Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.35 |
| ▸ | GSK3A | P49840 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | PRKX | P51817 | 2/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.35 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.35 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22895152 | 0.83 | CXCR2 (0.39) | PLK1CXCR2ROCK1CHEK1ROCK2 | |
| SCHEMBL9962285 | 0.83 | CXCR2 (0.40) | PLK1CXCR2ROCK1CHEK1ROCK2 | |
| SCHEMBL12784271 | 0.73 | CXCR2 (0.35) | PLK1CXCR2ROCK1CHEK1ROCK2 | |
| SCHEMBL16683780 | 0.73 | CXCR2 (0.36) | PLK1CXCR2ROCK1CHEK1ROCK2 | |
| SCHEMBL19196478 | 0.73 | CXCR2 (0.30) | PLK1CXCR2 | |
| SCHEMBL25477849 | 0.70 | CXCR2 (0.33) | PLK1CXCR2 | |
| SCHEMBL8229788 | 0.69 | CXCR2 (0.33) | CXCR2GAA | |
| SCHEMBL26721081 | 0.68 | PLK1 (0.33) | PLK1CXCR2ROCK1ROCK2CHEK2 | |
| SCHEMBL26546660 | 0.68 | HTT (0.35) | PLK1CXCR2ROCK1CHEK1ROCK2 | |
| SCHEMBL2625576 | 0.68 | LMNA (0.36) | PLK1CXCR2ROCK1CHEK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210284988-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-10780084-B2 | Antibody-recruiting molecules for the treatment of cancer | YALE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10703743-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703823-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127487-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2019-05-02 | — | — | US | disclosed |
| US-20190002447-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-03 | — | — | US | disclosed |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2018-07-10 | — | — | US | disclosed |
| US-9926275-B2 | Allosteric modulators of the cannabinoid 1 receptor | NORTHEASTERN UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926275-B2 | Allosteric modulators of the cannabinoid 1 receptor | NORTHEASTERN UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-09 | — | — | US | disclosed |
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160194284-A1 | ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR | NORTHEASTERN UNIVERSITY (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194284-A1 | ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR | CNR1, CNR2, GPR119 | PLK1 3433/4885CXCR2 2408/4885ROCK1 3808/4885 |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | PLK1 3409/4885CXCR2 672/4885ROCK1 3071/4885 |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | TLR3, TLR4, TLR1 | PLK1 766/4885CXCR2 274/4885ROCK1 3832/4885 |
| US-20210206757-A1 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | CCR6, CCR1, CCR3 | PLK1 3301/4885CXCR2 13/4885ROCK1 4522/4885 |
| US-10703743-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | PLK1 3307/4885CXCR2 2924/4885ROCK1 4240/4885 |
| US-20190002447-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | PLK1 3307/4885CXCR2 2924/4885ROCK1 4240/4885 |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | PLK1 274/4885CXCR2 3615/4885ROCK1 3136/4885 |
| US-20190127487-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | PLK1 302/4885CXCR2 584/4885ROCK1 2114/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | PLK1 4576/4885CXCR2 864/4885ROCK1 3383/4885 |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | PLK1 1306/4885CXCR2 3653/4885ROCK1 3438/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | PLK1 302/4885CXCR2 584/4885ROCK1 2114/4885 |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, ASGR1, FCGR2A | PLK1 3409/4885CXCR2 672/4885ROCK1 3071/4885 |
| US-20210284988-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | PLK1 242/4885CXCR2 216/4885ROCK1 1637/4885 |
| US-10703823-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | PLK1 302/4885CXCR2 584/4885ROCK1 2114/4885 |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | PLK1 1351/4885CXCR2 3819/4885ROCK1 3453/4885 |
| US-10780084-B2 | Antibody-recruiting molecules for the treatment of cancer | PLAUR, C3AR1, C5AR1 | PLK1 442/4885CXCR2 648/4885ROCK1 3153/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | PLK1 184/4885CXCR2 826/4885ROCK1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.